Imperia

Researchers are evaluating the effectiveness of Ravulizumab in improving the daily activities of people with early-stage generalized Myasthenia Gravis who test positive for anti-AChR antibodies. This real-world study also includes biomarker analysis to better understand the disease and treatment impact. The study is sponsored by Alexion Pharmaceuticals, Inc. and focuses on patients with recent diagnosis and moderate to severe disease severity. Participants will receive Ravulizumab treatment for up to 50 weeks, with a window of plus or minus 14 days from the start of the study or until they choose to stop. The treatment is given according to reimbursement criteria, and patients must have completed vaccination against Neisseria meningitidis or receive antibiotic prevention before starting. The study does not include a placebo or comparison group, focusing solely on the effects of Ravulizumab. Throughout the study, participants will have assessments at multiple points including weeks 2, 10, 26, and 50. These assessments will measure changes in muscle strength, daily living activities, quality of life, mood, insomnia, pain, medication usage, and productivity. Biomarker levels will also be analyzed at several visits. This comprehensive monitoring aims to track treatment response and safety over nearly one year of participation.